+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Cough - Pipeline Review, H2 2020

  • ID: 5146931
  • Drug Pipelines
  • August 2020
  • Region: Global
  • 116 pages
  • Global Markets Direct

FEATURED COMPANIES

  • Adare Pharmaceuticals Inc
  • Axalbion SA
  • Conrig Pharma ApS
  • Hyundai Pharma Co Ltd
  • NeRRe Therapeutics Ltd
  • PhytoHealth Corp
  • MORE
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Summary

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Cough - Pipeline Review, H2 2020, provides an overview of the Cough (Respiratory) pipeline landscape.

Cough is a reflex action that clears the throat of mucus or foreign irritants. Signs and symptoms include stuffy nose, hoarseness, wheezing and shortness of breath and heartburn or a sour taste in mouth. Risk factors include laryngopharyngeal reflux, allergies, reduced hydration, smoking, asthma, chronic bronchitis, gastroesophageal reflux and chemical sensitivities. Treatment for cough includes antihistamines, decongestants, antibiotics and cough suppressants.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Cough - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Cough (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cough (Respiratory) pipeline guide also reviews the key players involved in therapeutic development for Cough and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 3, 9, 4, 10, 1 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Cough (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Cough (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Cough (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Cough (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Cough (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Cough (Respiratory)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize the emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Cough (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Cough (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Adare Pharmaceuticals Inc
  • Axalbion SA
  • Conrig Pharma ApS
  • Hyundai Pharma Co Ltd
  • NeRRe Therapeutics Ltd
  • PhytoHealth Corp
  • MORE
Introduction
  • Cough - Overview
  • Cough - Therapeutics Development
Cough - Therapeutics Assessment

Cough - Companies Involved in Therapeutics Development

Cough - Drug Profiles

Cough - Dormant Projects
  • Cough - Discontinued Products
  • Cough - Product Development Milestones
Appendix

List of Tables
  • Number of Products under Development for Cough, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Companies, H2 2020 (Contd..1), H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020 (Contd..1), H2 2020
  • Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Stage and Target, H2 2020
  • Number of Products by Stage and Mechanism of Action, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Cough - Pipeline by Adare Pharmaceuticals Inc, H2 2020
  • Cough - Pipeline by Algernon Pharmaceuticals Inc, H2 2020
  • Cough - Pipeline by Alitair Pharmaceuticals Inc, H2 2020
  • Cough - Dormant Projects, H2 2020
  • Cough - Dormant Projects, H2 2020 (Contd..1), H2 2020
  • Cough - Dormant Projects, H2 2020 (Contd..2), H2 2020
  • Cough - Discontinued Products, H2 2020
List of Figures
  • Number of Products under Development for Cough, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products by Top 10 Targets, H2 2020
  • Number of Products by Stage and Top 10 Targets, H2 2020
  • Number of Products by Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Routes of Administration, H2 2020
  • Number of Products by Stage and Routes of Administration, H2 2020
  • Number of Products by Stage and Molecule Types, H2 2020
Note: Product cover images may vary from those shown
  • Adare Pharmaceuticals Inc
  • Algernon Pharmaceuticals Inc
  • Alitair Pharmaceuticals Inc
  • Antheia Inc
  • Asana BioSciences LLC
  • Axalbion SA
  • Bayer AG
  • Beijing Tide Pharmaceutical Co Ltd
  • BELLUS Health Inc
  • Charleston Laboratories Inc
  • Conrig Pharma ApS
  • Evotec SE
  • Grunenthal GmbH
  • Hyundai Pharma Co Ltd
  • Korea United Pharm Inc
  • Merck & Co Inc
  • NeRRe Therapeutics Ltd
  • Nocion Therapeutics Inc
  • Nuformix Plc
  • PhytoHealth Corp
  • Shionogi & Co Ltd
  • SolAeroMed Inc
  • Trevi Therapeutics Inc
  • Tris Pharma Inc
Note: Product cover images may vary from those shown
Adroll
adroll